« Return to News | Clinical Intelligence

Verinata study published in Obstetrics & Gynecology journal

Monday, February 27, 2012 10:01 AM

Obstetrics & Gynecology (Green journal) published full data from Verinata Health’s prospective, blinded, multi-center clinical validation study to detect fetal chromosomal aneuploidies across the entire genome using its verifi prenatal test.

The publication, titled "Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing," was selected as Editor's Choice of the peer-reviewed journal. Full study results are available in the online version, and a print version will be available in the May 2012 issue.

"When we designed this study, it was imperative that it emulate actual clinical practice, including all high-risk pregnant women, and importantly, detecting aneuploidy across the entire genome, where the genetic information about the fetus is unknown prior to this test," said Caren L. Mason, CEO of Verinata Health. "The clinical study demonstrated 100% specificity (no false positives) in the most prevalent trisomies.”

Verinata's proprietary verifi non-invasive prenatal test will include the detection of Down syndrome (trisomy 21), Edwards syndrome (trisomy 18) and Patau syndrome (trisomy 13) in the initial launch configuration.

Additional technical papers covering Verinata's methods in practice and continuing improvement in sequencing results are pending.

The verifi prenatal test will be available to clinicians in the U.S. March 1 and will include simplified sample collection methods, streamlined test reporting and less than a 1% no call rate. Verinata intends to expand the capabilities of the verifi prenatal test later in 2012.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.